SCHEMBL7984286

SCHEMBL7984286

Cc1c(Cl)ccnc1CO

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RECQL P46063 1/20 0.39
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NOTUM Q6P988 1/20 0.35
DYRK1A Q13627 1/20 0.33
SMARCA2 P51531 1/20 0.31
SMARCA4 P51532 1/20 0.31
KMT2A Q03164 1/20 0.31
AXL P30530 1/20 0.31
PRKCI P41743 1/20 0.31
SORT1 Q99523 2/20 0.30
NOS3 P29474 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30872392 1.00 ALDH1A1 (0.41) ALDH1A1L3MBTL1RECQLPDE3BPDE3A
Hydrochloric Acid SCHEMBL6868388 0.98 ALDH1A1 (0.39) ALDH1A1L3MBTL1RECQLPDE3BPDE3A
SCHEMBL7971571 0.81 AXL (0.31) ALDH1A1AXLPRKCINOS3NOS2
Hydrochloric Acid SCHEMBL3180486 0.79 AXL (0.31) ALDH1A1AXLPRKCINOS3NOS2
SCHEMBL21355820 0.79 LOXL2 (0.39) ALDH1A1KDM4EKMT2AAXLPRKCI
Hydrochloric Acid SCHEMBL6869748 0.79 AXL (0.31) ALDH1A1AXLPRKCINOS3NOS2
Hydrochloric Acid SCHEMBL7995412 0.79 AXL (0.31) ALDH1A1AXLPRKCINOS3NOS2
SCHEMBL30506625 0.79 LOXL2 (0.39) ALDH1A1KDM4EKMT2AAXLPRKCI
SCHEMBL2083503 0.78 NOS2 (0.46) ALDH1A1L3MBTL1RECQLPDE3BPDE3A
SCHEMBL7012351 0.78 ALDH1A1 (0.43) ALDH1A1L3MBTL1RECQLPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981671-B2 Bicyclic pyrazolyl amines as CDK2 inhibitors INCYTE CORPORATION (US) 2024-05-14 US disclosed
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS VERNALIS (R&D) LTD (GB) 2024-05-09 US disclosed
EP-4277892-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2023-11-22 EP disclosed
CN-116940552-A Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2023-10-24 CN disclosed
WO-2023134713-A1 FUSED AZAHETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 南方科技大学 2023-07-20 WO disclosed
US-20230002376-A1 BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-01-05 US disclosed
US-20230002376-A1 BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-01-05 US disclosed
WO-2022152705-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-07-21 WO disclosed
US-20210363139-A1 CXCR4 INHIBITORS AND USES THEREOF X4 PHARMACEUTICALS, INC. 2021-11-25 US disclosed
US-10988465-B2 CXCR4 inhibitors and uses thereof X4 PHARMACEUTICALS, INC. (US) 2021-04-27 US disclosed
CN-102399212-A Dexlansoprazole crystal form and preparation method thereof JIANGSU HANSOH MEDICAL GROUP CO LTD 2012-04-04 CN disclosed
CN-102108076-A Method for preparing amorphous dexlansoprazole JIANGSU HANSOH MEDICAL GROUP CO LTD 2011-06-29 CN disclosed
CN-102108077-A Method for preparing dexlansoprazole JIANGSU HANSOH MEDICAL GROUP CO LTD 2011-06-29 CN disclosed
CN-1789251-A Production method of prazole heterocyclic compound and salt thereof JIANGSU HAOSEN PHARMACEUTICAL (CN) 2006-06-21 CN disclosed
CN-1070488-C Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria BYK GULDEN LOMBERG CHEM FAB (DE) 2001-09-05 CN disclosed
WO-2001004109-A1 PROCESS FOR THE PRODUCTION OF 2-(2-PYRIDINYLMETHYLSULPHINYL)-1H-BENZIMIDAZOLES QUIMICA SINTETICA, S.A. (ES) 2001-01-18 WO disclosed
US-5859030-A Substituted arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1999-01-12 US disclosed
CN-1159803-A Substituted Arylalkylthioalkylthiopyridines for use in the control of helicobacter bacteria BYK GULDEN LOMBERG CHEM FAB (DE) 1997-09-17 CN disclosed
EP-0764161-A1 SUBSTITUTED ARYLALKYLTHIOALKYLTHIOPYRIDINES FOR USE IN THE CONTROL OF HELICOBACTER BACTERIA Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1997-03-26 EP disclosed
WO-1995034554-A1 SUBSTITUTED ARYLALKYLTHIOALKYLTHIOPYRIDINES FOR USE IN THE CONTROL OF HELICOBACTER BACTERIA BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1995-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BAX, BCL2A1 ALDH1A1 1439/4885L3MBTL1 2956/4885RECQL 836/4885
US-20230002376-A1 BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS CDK2, CCNI, CDK1 ALDH1A1 2543/4885L3MBTL1 4615/4885RECQL 849/4885
US-11981671-B2 Bicyclic pyrazolyl amines as CDK2 inhibitors CDK2, CCNI, CDK1 ALDH1A1 2543/4885L3MBTL1 4615/4885RECQL 849/4885
US-20210363139-A1 CXCR4 INHIBITORS AND USES THEREOF CXCR4, CXCL12, CXCR3 ALDH1A1 1512/4885L3MBTL1 3322/4885RECQL 4421/4885
US-10988465-B2 CXCR4 inhibitors and uses thereof CXCR4, CXCL12, CXCR3 ALDH1A1 1512/4885L3MBTL1 3322/4885RECQL 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.